Scilex Gets Orphan Drug Designation for Its Version of Colchicine

Dow Jones

Apr 17

By Josh Beckerman

Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis.

The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares.

Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday.

The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

April 16, 2025 14:39 ET (18:39 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2528279819"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2528279819\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2528279819?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 02:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528279819","market":"other","top_or_hot":-1,"title":"Scilex Gets Orphan Drug Designation for Its Version of Colchicine","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n</p>\n<p>\n  The company's Gloperba, licensed from Romeg <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n</p>\n<p>\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n</p>\n<p>\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 14:39 ET (18:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scilex Gets Orphan Drug Designation for Its Version of Colchicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScilex Gets Orphan Drug Designation for Its Version of Colchicine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-17 02:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n</p>\n<p>\n  The company's Gloperba, licensed from Romeg <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n</p>\n<p>\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n</p>\n<p>\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 14:39 ET (18:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCLX","symbol_name":"Scilex Holding Company","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2528279819","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528279819","pubTimestamp":1744828740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis.The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares.Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday.The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCLX":"Scilex Holding Company","BK4007":"制药"},"translate_title":"Scilex的秋水仙碱获得孤儿药称号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCLX":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n\n\n  The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n\n\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n\n\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 14:39 ET (18:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}